Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00503009 · ClinicalTrials.gov registry record · Phase 4
Study Of RV-39 In Patients Who Also Have Asthma
A Phase 4 study, sponsored by GlaxoSmithKline.
- Terminated
- Registry status
- Phase 4
- Development phase
- 16
- Enrollment target
NCT00503009 is a Phase 4 study that was terminated before completion, run by GlaxoSmithKline. The registered enrollment target is 16 participants.
The verdict
NCT00503009, a Phase 4 study, was terminated before completion, sponsored by GlaxoSmithKline.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 16 participants
- Enrollment target
Study Summary
This study will last up to 9 weeks. Subjects will visit the clinic up to 14 times. Certain clinic visits will include a physical examination, lung function tests, inflammatory cell analysis from nasal secretions and/or sputum, and blood draws. Subjects will inhale an FDA approved virus through their nose which is known to cause the common cold. All study related medications and medical examinations will be provided at no cost to the subject. The drugs used in this study are approved for the age group under study.
Interventions
- DRUG placebo
- DRUG fluticasone propionate
- DRUG fluticasone propionate/salmeterol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2007-10 |
| Est. Completion | 2008-07 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00503009
The ClinicalTrials.gov registry entry for NCT00503009 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which placebo is the first listed.
NCT00503009 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00503009 about?
NCT00503009 is a clinical study titled "Study Of RV-39 In Patients Who Also Have Asthma". This study will last up to 9 weeks. Subjects will visit the clinic up to 14 times. Certain clinic visits will include a physical examination, lung function tests, inflammatory cell analysis from nasal secretions and/or sputum, and blood draws. Subjects will inhale an FDA approved virus through their...
What is the current status of trial NCT00503009?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 16 participants. The study started on 2007-10. Estimated completion is 2008-07.
What interventions are being tested in trial NCT00503009?
The interventions under investigation include: placebo (DRUG), fluticasone propionate (DRUG), fluticasone propionate/salmeterol (DRUG).
Who is sponsoring clinical trial NCT00503009?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.